Protagonist Therapeutics, Inc
ICOTYDE
plaque psoriasis
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on ICOTYDE for plaque psoriasis is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“A U.S. regulatory decision is anticipated in 2026, followed by commercial launch this year, if FDA approval is granted.”